Posted by Michael Wonder on 05 Aug 2019
Foamix submits new drug application to U.S. FDA for FMX103 for the treatment of moderate-to-severe papulopustular rosacea
5 August 2019 - Foamix Pharmaceuticals today announced that it has submitted a new drug application to the U.S. FDA seeking approval for FMX103 for the treatment of moderate-to-severe papulopustular rosacea in patients 18 years of age and older.
The submission is supported by the previously communicated results from two Phase 3 clinical trials, FX2016-11 and FX2016-12.
